Update on Passage Bio’s MLD program

Passage Bio have submitted an Investigational New Drug (IND) application to FDA for a Phase 1/2 clinical trial of PBML04 in MLD. Following the FDA review, they plan to provide more information about the MLD clinical program.

To read full press release: Passage Bio Press Release